モノクローナル抗体(mAbs)の世界市場2016-2020...市場調査レポートについてご紹介

【英文タイトル】Global Monoclonal Antibodies Market 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Assumptions
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: mAbs: Overview
• Evolution of mAb therapeutics
• Types of mAbs
• Conjugated cancer therapies using mAbs

PART 06: Market landscape
• Market overview
• Five forces analysis

PART 07: Market segmentation by type of mAbs
• Naked mAbs
• Conjugated mAbs

PART 08: Market segmentation by application
• Global oncology mAbs market
• Global autoimmune and inflammatory mAbs market
• TNF inhibitors
• IL-1 blockers
• PDE4 inhibitors
• Global respiratory mAbs market
• Global ophthalmology mAbs market

PART 09: Geographical segmentation
• Global mAbs market by geographical segmentation 2015-2020
• mAbs market in Americas
• mAbs market in US
• mAbs market in EMEA
• mAbs market in APAC

PART 10: Key leading countries

PART 11: Pipeline portfolio

PART 12: Market drivers
• Reimbursement benefits for mAbs and its biosimilars
• Special regulatory drug designations
• Increase in demand for ADCs
• Increase in industry-academia collaborations

PART 13: Impact of drivers

PART 14: Market challenges0
• Absence of adequate diagnosis and screening procedures
• High manufacturing costs coupled with stringent regulations
• Threat from chemotherapy and off-label drugs
• Difficulties in patient recruitment for conducting clinical trials

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Emergence of biosimilars
• Growing focus of vendors on untapped markets
• Focus on novel mechanisms
• Joint ventures and partnerships for R&D
• Emergence of targeted and combination therapies

PART 17: Vendor landscape
• Competitive scenario
• Key news
• F. Hoffmann-La Roche
• AbbVie
• Johnson & Johnson
• Amgen
• Merck
• BMS
• Other prominent vendors

PART 18: Appendix
• List of abbreviations

PART 19: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for mAbs 2015
Exhibit 03: Impact of key customer segments on market 2015
Exhibit 04: Comparison of small molecule and mAbs
Exhibit 05: Preparation of mAbs
Exhibit 06: Types of mAbs
Exhibit 07: Targeted mechanisms of cancer mAbs
Exhibit 08: Patent expiries of top selling mAbs by 2020 in US
Exhibit 09: Patent expiries of top selling mAbs by 2020 in Europe
Exhibit 10: Global mAbs market snapshot: Developed and emerging markets 2015
Exhibit 11: Global mAbs market 2015-2020 ($ billions)
Exhibit 12: Few patient assistance programs offered by various companies
Exhibit 13: Few awareness programs for various cancers, respiratory, and ophthalmology diseases
Exhibit 14: Impact of drivers and challenges on global mAbs market
Exhibit 15: Competitive assessment of marketed and late-stage pipeline molecules
Exhibit 16: Opportunities in mAbs industry today
Exhibit 17: Five forces analysis
Exhibit 18: Approved naked mAbs by US FDA and EU
Exhibit 19: Global mAbs market: Segmentation by application (2015-2020)
Exhibit 20: Global mAbs market: Segmentation by application 2015
Exhibit 21: Global mAbs market segmentation: Growth cycle analysis
Exhibit 22: Annual treatment cost per patient for various oncology drugs 2014
Exhibit 23: Global oncology mAbs market 2015-2020 ($ billions)
Exhibit 24: Opportunity analysis of global oncology mAbs market by type of application
Exhibit 25: Market segmentation by MOA
Exhibit 26: Population aged 60 years and over (millions)
Exhibit 27: Average annual treatment cost of adalimumab, etanercept, and infliximab 2014 ($ millions)
Exhibit 28: Global autoimmune and inflammatory mAbs market 2015-2020 ($ billions)
Exhibit 29: Opportunity analysis of global autoimmune and inflammatory mAbs market by application
Exhibit 30: Global autoimmune and inflammatory mAbs market segmentation by MOA
Exhibit 31: Average percentage of patients receiving TNF inhibitors 2010 and 2015
Exhibit 32: Global autoimmune and inflammatory mAbs market share by MOA 2015
Exhibit 33: Global respiratory mAbs market 2015-2020 ($ billions)
Exhibit 34: Opportunity analysis of global respiratory mAbs market by application
Exhibit 35: Global mAbs market segmentation by application 2015
Exhibit 36: Global ophthalmology mAbs market 2015-2020 ($ billions)
Exhibit 37: Opportunity analysis of global ophthalmology mAbs market by application
Exhibit 38: Global mAbs market: Geography outlook (2015-2020)
Exhibit 39: Global mAbs market: Geography outlook 2015
Exhibit 40: Revenue/growth outlook in different countries/regions 2015
Exhibit 41: mAbs market in Americas 2015-2020 ($ billions)
Exhibit 42: mAbs market in Americas by country 2015
Exhibit 43: mAbs market in US 2015-2020 ($ billions)
Exhibit 44: mAbs market in EMEA 2015-2020 ($ billions)
Exhibit 45: mAbs market in EMEA by country 2015
Exhibit 46: Number of individuals treated with Herceptin through patient assistance programs in China
Exhibit 47: mAbs market in APAC 2015-2020 ($ billions)
Exhibit 48: mAbs market in APAC by country 2015
Exhibit 49: Global mAbs market by geographical segmentation 2015
Exhibit 50: Global mAbs market by geographical segmentation 2020
Exhibit 51: Global mAbs market revenue by geography 2015-2020 ($ billions)
Exhibit 52: Key leading countries
Exhibit 53: Pipeline share of global mAbs market 2015
Exhibit 54: Phase III pipeline molecules for mAbs
Exhibit 55: Phase II pipeline molecules for mAbs
Exhibit 56: Phase I pipeline molecules for mAbs
Exhibit 57: Special regulatory designations approved by US FDA
Exhibit 58: Special regulatory designations approved by EU
Exhibit 59: Impact of drivers
Exhibit 60: Impact of drivers and challenges
Exhibit 61: Expected combination regimen launches in oncology
Exhibit 62: Global mAbs market: Impact assessment of top trends 2015
Exhibit 63: Market presence of vendors in various therapy areas 2015
Exhibit 64: Market share analysis 2015
Exhibit 65: YoY sales comparison of top ten mAbs 2013-2015 ($ billions)
Exhibit 66: Competitive assessment of vendors
Exhibit 67: Key vendors: Geographical presence 2015
Exhibit 68: F. Hoffmann-La Roche: YoY growth and revenue of MabThera/Rituxan 2013-2015 ($ billions)
Exhibit 69: F. Hoffmann-La Roche: Geographic segmentation of MabThera/Rituxan by revenue 2015
Exhibit 70: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Avastin 2013-2015 ($ billions)
Exhibit 71: F. Hoffmann-La Roche: Geographic segmentation of Avastin by revenue 2015
Exhibit 72: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Herceptin 2013-2015 ($ billions)
Exhibit 73: F. Hoffmann-La Roche: Geographical segmentation of Herceptin 2015
Exhibit 74: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Lucentis 2013-2015 ($ billions)
Exhibit 75: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Perjeta 2013-2015 ($ billions)
Exhibit 76: F. Hoffmann-La Roche: Geographical segmentation of Perjeta 2015
Exhibit 77: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Xolair 2013-2015 ($ billions)
Exhibit 78: F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions)
Exhibit 79: F. Hoffmann-La Roche: Geographical segmentation of Kadcyla 2015
Exhibit 80: Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)
Exhibit 81: Actemra/RoActemra geographic segmentation by revenue 2015
Exhibit 82: F Hoffmann-La Roche: Metrics analysis
Exhibit 83: AbbVie: YoY revenue and growth rate of Humira 2013-2015 ($ billions)
Exhibit 84: AbbVie: YoY revenue and growth rate of Humira (US) 2013-2015 ($ billions)
Exhibit 85: AbbVie: YoY revenue and growth rate of Humira (ROW) 2013-2015 ($ billions)
Exhibit 86: AbbVie: YoY revenue and growth rate of Synagis 2013-2015 ($ millions)
Exhibit 87: AbbVie: Metrics analysis
Exhibit 88: Johnson & Johnson: YoY growth rate and revenue of Remicade 2013-2015 ($ billions)
Exhibit 89: Johnson & Johnson: YoY growth rate and revenue of Remicade (US) 2013-2015 ($ billions)
Exhibit 90: Johnson & Johnson: YoY growth rate and revenue of Remicade (ROW) 2013-2015 ($ billions)
Exhibit 91: Johnson & Johnson: YoY growth rate and revenue of Stelara 2013-2015 ($ billions)
Exhibit 92: Johnson & Johnson: YoY growth rate and revenue of Stelara (US) 2013-2015 ($ millions)
Exhibit 93: Johnson & Johnson: YoY growth rate and revenue of Stelara (ROW) 2013-2015 ($ millions)
Exhibit 94: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2013-2015 ($ millions)
Exhibit 95: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (US) 2013-2015 ($ millions)
Exhibit 96: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (ROW) 2013-2015 ($ millions)
Exhibit 97: Johnson & Johnson: Metrics analysis
Exhibit 98: Amgen: YoY growth and revenue generated from net product sales of Xgeva 2013-2015 ($ billions)
Exhibit 99: Amgen: Geographic segmentation of Xgeva 2015
Exhibit 100: Amgen: YoY growth and revenue generated from net product sales of Prolia 2013-2015 ($ billions)
Exhibit 101: Amgen: Geographical segmentation of Prolia 2015
Exhibit 102: Amgen: YoY growth and revenue generated from net product sales of Vectibix 2013-2015 ($ millions)
Exhibit 103: Amgen: Geographical segmentation of Vectibix 2015
Exhibit 104: Amgen: Metrics analysis
Exhibit 105: Merck: YoY revenue and growth rate of Remicade (Europe, Russia, and Turkey) 2013-2015 ($ billions)
Exhibit 106: Merck: YoY revenue and growth rate of Simponi (Europe, Russia, and Turkey) 2013-2015 ($ millions)
Exhibit 107: Merck: Metrics analysis
Exhibit 108: BMS: YoY growth and revenue generated from net product sales of Yervoy 2011-2014 ($ billions)
Exhibit 109: BMS: Geographical segmentation of Yervoy 2015
Exhibit 110: BMS: YoY Revenue and growth rate of Erbitux in US and Canada 2013-2015 ($ millions)
Exhibit 111: BMS: Geographical segmentation of Yervoy 2015
Exhibit 112: BMS: Geographical segmentation of Opdivo 2015
Exhibit 113: BMS: Metrics analysis


【レポート販売概要】

■ タイトル:モノクローナル抗体(mAbs)の世界市場2016-2020
■ 英文:Global Monoclonal Antibodies Market 2016-2020
■ 発行日:2016年7月20日
■ 調査会社:Technavio
■ 商品コード:IRTNTR9857
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。